Sanofi GCVRZ 深 沪
交易中 02-02 09:47:26 美东时间
0.8711
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 总市值 1113.52亿
- 52周最高 0.882
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 总股本 1278.30亿
- 历史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.153
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
The European Medicine Association's Committee for Medicinal Products for Human Use has given a positive recommendation for conditional approval to Sanofi's (SNY) chronic graft-versus-host disease trea...
01-30 21:51
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms
FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms Changes dateline, adds Eli Lilly details in paragraph 11 Jan 30 (Reuters) - Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers a 100% tariff on imported branded
01-30 20:07
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA Overview Biotechnology firm's Q4 revenue rose 3%, beating analyst expectations Adjusted EPS for Q4 beat analyst expectations Company announced FDA approvals for EYLEA HD and Libtayo Outlook Regeneron expects 2026 GAAP R&D
01-30 19:42
Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks
Sanofi SA (NASDAQ: SNY) reported Q4 sales of $13.159B, missing consensus of $13.41B. CEO expects profitable growth to continue over 5 years.
01-29 20:08
UPDATE 3-Sanofi vaccine sales face headwinds from US policy shifts
UPDATE 3-Sanofi vaccine sales face headwinds from US policy shifts Blockbuster drug Dupixent too big to be mitigated, CFO says Expects continued M&A activity this year CEO sees opportunity for vaccine-focused deals Vaccine sales likely 'slightly negative' this year on US weakness Recasts with CEO co
01-29 15:11
Sanofi Q4 Adj. EPS $0.89 Beats $0.84 Estimate
Sanofi (NASDAQ:SNY) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.84 by 5.95 percent.
01-29 15:00
Sanofi Q4 Sales $13.159B Miss $13.410B Estimate
Sanofi (NASDAQ:SNY) reported quarterly sales of $13.159 billion which missed the analyst consensus estimate of $13.410 billion by 1.87 percent. This is a 16.71 percent increase over sales of $11.275 billion the same
01-29 14:39
Sanofi targets high single digit sales growth in 2026, plans share buyback
Sanofi targets high single digit sales growth in 2026, plans share buyback LONDON, Jan 29 (Reuters) - French drugmaker Sanofi SASY.PA said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer
01-29 14:30
Deutsche Bank Remains a Buy on Sanofi (SNYNF)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a ...
01-27 17:15
杰富瑞：赛诺菲湿疹治疗药物多项试验结果喜忧参半
Jefferies分析师Michael Leuchten在一份报告中写道，赛诺菲(Sanofi)的湿疹治疗药物amlitelimab在多项试验中结果喜忧参半。...
01-23 19:27
